ID: ALA5269955

Max Phase: Preclinical

Molecular Formula: C42H48N10O9

Molecular Weight: 836.91

Representations

Canonical SMILES:  CCCCN(Cc1ccc(C(=O)NO)cc1)C(=O)Nc1ccc(NC(=O)CCCc2cn(CCOCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)nn2)cc1

Standard InChI:  InChI=1S/C42H48N10O9/c1-2-3-21-50(25-27-10-12-28(13-11-27)38(55)48-60)42(59)45-30-16-14-29(15-17-30)44-35(53)9-4-6-31-26-51(49-47-31)22-24-61-23-20-43-33-8-5-7-32-37(33)41(58)52(40(32)57)34-18-19-36(54)46-39(34)56/h5,7-8,10-17,26,34,43,60H,2-4,6,9,18-25H2,1H3,(H,44,53)(H,45,59)(H,48,55)(H,46,54,56)

Standard InChI Key:  ASTBYSZIHNGCIB-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 836.91

Molecular Weight (Monoisotopic): 836.3606

AlogP: 3.72

#Rotatable Bonds: 20

Polar Surface Area: 246.29

Molecular Species: NEUTRAL

HBA: 13

HBD: 6

#RO5 Violations: 3

HBA (Lipinski): 19

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 9.05

CX Basic pKa: 1.49

CX LogP: 3.02

CX LogD: 3.01

Aromatic Rings: 4

Heavy Atoms: 61

QED Weighted: 0.03

Np Likeness Score: -1.34

References

1. Tomaselli D, Mautone N, Mai A, Rotili D..  (2020)  Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).,  207  [PMID:32871345] [10.1016/j.ejmech.2020.112750]

2. Wang C, Zhang Y, Wu Y, Xing D..  (2021)  Developments of CRBN-based PROTACs as potential therapeutic agents.,  225  [PMID:34411892] [10.1016/j.ejmech.2021.113749]

3. Li D, Yu D, Li Y, Yang R..  (2022)  A bibliometric analysis of PROTAC from 2001 to 2021.,  244  [PMID:36274273] [10.1016/j.ejmech.2022.114838]

Source

Source(1):

• Scientific Literature